

# Pharmaceuticals UltraSector ProFund

## Investor Class PPIX



Semi-annual Shareholder Report – January 31, 2026

### Fund Overview

This Semi-annual shareholder report contains important information about the Pharmaceuticals UltraSector ProFund (the "Fund") for the period of August 1, 2025 to January 31, 2026. You can find additional information about the Fund at <https://www.profund.com/literature>. You can also request this information by contacting us at 888-776-3637.

### What were the Fund's costs for the last six months?

(based on a hypothetical \$10,000 investment)

Class Name	Costs of a \$10,000 investment	Costs paid as a percentage of a \$10,000 investment
Investor Class	\$113	1.78%

#### Fund Statistics

Net Assets	\$3,902,249
Number of Holdings*	64
Net Investment Advisory Fees	\$9,043
Portfolio Turnover	194%

\* No. of Holdings excludes any derivatives and collateral for securities loaned.

#### Largest Sector Weights

Sector	Weight
Pharmaceuticals	100%

#### Market Exposure

Investment Type	% of Net Assets
Equity Securities	78%
S&P Pharmaceuticals Select Industry Index Swap Agreements	71%
<b>Total</b>	<b>149%</b>

#### Largest Equity Holdings

Holding	% of Net Assets
Definium Therapeutics, Inc.	2.0%
Liquidia Corp.	1.9%
MBX Biosciences, Inc.	1.9%
Axsome Therapeutics, Inc.	1.8%
Organon & Co.	1.8%

"Market Exposure" includes the value of total investments (including the contract value of any derivatives) and excludes any short-term investments and instruments used for cash management.

## Pharmaceuticals UltraSector ProFund

Investor Class PPIX

Semi-annual Shareholder Report – January 31, 2026

Additional information about the Fund including the Financial Statements, Prospectus and Statement of Additional Information is available: On the Fund's website, <https://www.profund.com/literature>, or upon request, by calling 888-776-3637.

